Personal tools
Search Web Site
Project Topics

Adverse Event Reporting

State of Clinical Trials Enterprise

Study Quality

Study Start-Up

Patient representative sought for CTTI Steering Committee

CTTI is seeking a qualified patient representative to fill one of two designated patient seats on its Steering Committee.  Interested candidates should read the informational materials below to gain an understanding of the Patient Representative responsibilities and submit the required materials to CTTI@duke.edu by 5:00pm on October 12, 2012 for consideration.

Request for applications

Supplemental information form

 
middle

CaliffCaliff comments on drug makers in joint effort to streamline clinical trials

This week, the New York Times reported that ten of the world's largest pharmaceutical companies said that they would cooperate on research aimed at accelerating drug development, starting with streamlining clinical trials.

Pharmaceutical companies have collaborated before on areas considered not directly competitive, like finding variants in the human genome and biomarkers to predict disease and the effectiveness of drugs. But the people behind the new effort said it would be the largest of its kind. Read more...

 


Pamela TenaertsNew Executive Committee named to CTTI

The Clinical Trials Transformation Initiative (CTTI) has named a 14-member Executive Committee, resetting CTTI's strategic direction, and ensuring that the organization informs and facilitates meaningful improvements to clinical trial design and conduct. "Clinical trials are a critical component of how we develop medical evidence, and they are not meeting the societal need for answers about which strategies and therapies are most effective," said Robert Califf, M.D., co-chair of the CTTI Executive Committee, vice chancellor for clinical and translational research at Duke University Medical Center, and director of the Duke Translational Medicine Institute. "We believe we can improve the system in a major way through focused effort of the entire clinical research community, including patients themselves. The CTTI Executive Committee understands the need to transform clinical trials, as well as how to do so in ways that align the mutual interests of patients, investigators, and companies that develop medical products. Under this new leadership, CTTI will be able to make substantial improvements to the conduct of clinical trials." Read more...

Funding and other support

 

CTTI receives financial and in-kind support from many groups committed to improving clinical trials. Member organizations pay an annual fee which supports CTTI infrastructure expenses and projects.  The Executive Committee oversees the use of these funds.  In addition, individuals from many member organizations, and some non-member organizations, contribute time and other resources to make CTTI projects successful.  The sources of support for each project can be found on the respective project pages of the website.

Duke University, as the host of CTTI, has also received a cooperative agreement from the U.S. Food and Drug Administration (grant U19 FD003800) which provides some support for all current projects.